ArticleOncoscience2014
The combinatorial complexity of cancer precision medicine.
Article in Oncoscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- End-to-EndProceedings. IEEE International Conference on Healthcare Informatics · 2023Article
- RAPID framework for improved access to precision oncology for lethal disease: Results from a modified multi-round delphi study.Frontiers in health services · 2023Article
- Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.BMC medicine · 2022Article
- EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies.Cancers · 2022Review
- Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs.Statistics in medicine · 2021Article
- The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care.Scientific reports · 2021Article
- [Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- Article
- A System Biology-Based Approach for Designing Combination Therapy in Cancer Precision Medicine.BioMed research international · 2020Article
- Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.BMC cancer · 2019Article
- Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?Clinical pharmacology and therapeutics · 2019Article
- Systems proteogenomics for precision oncology.Oncotarget · 2019Article
- Physiological random processes in precision cancer therapy.PloS one · 2018Article
- Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology.Frontiers in medicine · 2018Article
- DNA methylation aberrancies as a guide for surveillance and treatment of human cancers.Epigenetics · 2017Review
- Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Review
- "Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?Clinical pharmacology and therapeutics · 2016Article
- Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric andTeen Patients Allows Identifying Two Main Classes of Biological ProcessesInvolved and New Potential Therapeutic Targets.Current genomics · 2016Article
- The hallmarks of premalignant conditions: a molecular basis for cancer prevention.Seminars in oncology · 2016Review
- Precision medicine for acute myeloid leukemia.Expert review of hematology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine approaches have recently been developed that offer therapies targeting mainly single genetic alterations in malignant tumors. However, next generation sequencing studies have shown that tumors normally harbor multiple genetic alterations, which could explain the so far limited successes of personalized medicine, despite considerable benefits in certain cases. Combination therapies may contribute to a solution, but will pose a major challenge for clinical trials evaluating those therapies. As we discuss here, reasons include the low abundance of most of the relevant mutations and particularly the combinatorial complexity of possible combination therapies. Our report provides a systematic and quantitative account of the implications of combinatorial complexity for cancer precision medicine and clinical trial design. We also present an outlook on how systems biological approaches may be harnessed to contribute to a solution of the complexity challenge by predicting optimal combination therapies for individual patients and how clinical trial design may be adapted by combining and extending basket and umbrella design features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.